Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor - secreting breast tumor vaccine: A chemotherapy dose-ranging factorial study of safety and immune activation

Journal of Clinical Oncology

Volumn 27, Issue 35, 2009, Pages 5911-5918

  Emens, Leisha A ^a   Asquith, Justin M ^a   Leatherman, James M ^a   Kobrin, Barry J ^a   Petrik, Silvia ^a   Laiko, Marina ^a   Levi, Joy ^a   Daphtary, Maithili M ^a   Biedrzycki, Barbara ^a   Wolff, Antonio C ^a   Stearns, Vered ^a   Disis, Mary L ^a   Ye, Xiaobu ^a   Piantadosi, Steven ^a   Fetting, John H ^a   Davidson, Nancy E ^a   Jaffee, Elizabeth M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HER2 PROTEIN, HUMAN;

ADULT; AGED; ANOREXIA; ANTIBODY RESPONSE; ANXIETY; ARTICLE; BLISTER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CHILL; CLINICAL ARTICLE; DESQUAMATION; DRUG DETERMINATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; ECCHYMOSIS; ECZEMA; ERYTHEMA; FACTORIAL DESIGN; FATIGUE; FEVER; HEADACHE; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; LOW DRUG DOSE; LYMPH NODE PAIN; LYMPHADENOPATHY; MALAISE; METASTASIS; MYALGIA; NAUSEA; PATIENT SELECTION; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; URTICARIA; ADOPTIVE IMMUNOTHERAPY; BIOSYNTHESIS; BLOOD; BREAST TUMOR; CD4+ T LYMPHOCYTE; CELL LINE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; GENETIC TRANSFECTION; GENETICS; IMMUNIZATION; IMMUNOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOTHERAPY, ADOPTIVE; MIDDLE AGED; RECEPTOR, ERBB-2; TIME FACTORS; TRANSFECTION; TREATMENT OUTCOME;

EID: 73349084990     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.3494     Document Type: Article

References (48)

1. American Cancer Society: Breast Cancer Facts and Figures 2005-2006. Atlanta, GA, ACS, 2005
2. Emens LA, Jaffee EM: Toward a breast cancer vaccine: Work in progress. Oncology (Williston Park) 17:1200-1211, 2003
3. Emens LA, Jaffee EM: Cancer vaccines: An old idea comes of age. Cancer Biol Ther 2:S161-S168, 2003
4. Dranoff G, Jaffee E, Lazenby A, et al: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90:3539-3543, 1993
5. Jaffee EM, Hruban RH, Biedrzycki B, et al: Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A Phase I trial of safety and immune activation. J Clin Oncol 19:145-156, 2001
6. Laheru D, Lutz E, Burke J, et al: Allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: A pilot study of safety, feasibility, and immune activation. Clin Cancer Res 14:1455-1463, 2008
7. Nemunaitis J, Sterman D, Jablons D, et al: Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 96:326-331, 2004
8. Simons JW, Carducci MA, Mikhak B, et al: Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naicombining diaeresisve prostate cancer. Clin Cancer Res 12:3394-3401, 2006
9. Simons JW, Jaffee EM, Weber CE, et al: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocytemacrophage colony-stimulating factor gene transfer. Cancer Res 57:1537-1546, 1997
10. Simons JW, Mikhak B, Chang JF, et al: Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59:5160-5168, 1999
11. Small EJ, Sacks N, Nemunaitis J, et al: Granulocyte macrophage colony-stimulating factor-secreting allogeneic immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 13:3883-3891, 2007
12. Soiffer R, Hodi FS, Haluska F, et al: Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 21:3343-3350, 2003
13. Soiffer R, Lynch T, Mihm M, et al: Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A 95:13141-13146, 1998
14. Emens LA, Reilly RT, Jaffee EM: Breast cancer vaccines: Maximizing cancer treatment by tapping into host immunity. Endocr Relat Cancer 12:1-17, 2005
15. Reilly RT, Gottlieb MB, Ercolini AM, et al: HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res 60:3569-3576, 2000
16. Machiels JP, Reilly RT, Emens LA, et al: Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage- colony stimulating factor-secreting wholecell vaccines in HER-2/neu tolerized mice. Cancer Res 61:3689-3697, 2001
17. Ercolini AM, Ladle BH, Manning EA, et al: Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 201:1591-1602, 2005
18. Curiel TJ, Coukos G, Zou L, et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949, 2004
19. Liyanage UK, Moore TT, Joo HG, et al: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with breast or pancreas adenocarcinomas. J Immunol 169:2756-2761, 2002
20. Viguier M, Lemaître F, Verola O, et al: FoxP3-expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173:1444-1453, 2004
21. Wolf AM, Wolf D, Steurer M, et al: Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606-612, 2003
22. Woo EY, Chu CS, Goletz TJ, et al: Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61:4766-4772, 2001
23. Woo EY, Yeh H, Chu CS, et al: Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168:4272-4276, 2002
24. Piantadosi S: Clinical Trials: A Methodologic Perspective (ed 2). New York, NY, Wiley Series in Probability and Statistics, 2005
25. Emens LA, Armstrong D, Biedrzycki B, et al: A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. Hum Gene Ther 15:313-337, 2004
26. Davis-Sproul JM, Harris MP, Davidson NE, et al: Cost-effective manufacture of an allogeneic GMCSF-secreting breast tumor vaccine in an academic cGMP facility. Cytotherapy 7:46-56, 2005
27. Disis ML, Schiffman K, Gooley TA, et al: Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin Cancer Res 6:1347-1350, 2000
28. Goodell V, Disis ML: Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity. J Immunol Methods 299:129-138, 2005
29. Hung HMJ, Chi GYH, Lipicky RJ: On some statistical methods for analysis of combination drug study. Commun Statist-Theory Meth 23:361-376, 1994
30. Myers RH, Khuri AI, Carter WH Jr: Response surface methodology: 1966-1988. Technometrics 31:137-157, 1989
31. Myers RH, Montgomery DC: Response Surface Methodology: Process and Product Optimization Using Designed Experiments. New York, NY, Wiley, 2002
32. SAS/STAT User's Guide, Version 8. Cary, NC, SAS Institute, 1999
33. Jaffee EM, Thomas MC, Huang AY, et al: Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J Immunother Emphasis Tumor Immunol 19:176-183, 1996
34. Thomas MC, Greten TF, Pardoll DM, et al: Enhanced tumor protection by granulocytemacrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum Gene Ther 9:835-843, 1998
35. Emens LA, Jaffee EM: Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 65:8059-8064, 2005
36. Schiavoni G, Mattei F, Di Puchio T, et al: Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: Implications for strategies of chemoimmuno-therapy of cancer. Blood 95:2024-2030, 2000
37. Ghiringhelli F, Larmonier N, Schmitt E, et al: CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34:336-344, 2004
38. Lutsiak ME, Semnani RT, De Pascalis R, et al: Inhibition of CD4(+)CD25+ T regulatory cell function implicated in enhanced immune response by low dose cyclophosphamide. Blood 105:2862-2868, 2005
39. Litzinger MT, Fernando R, Curiel TJ, et al: IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T cell immunity. Blood 110:3192-3201, 2007
40. Audia S, Nicolas A, Cathelin D, et al: Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: A Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes. Clin Exp Immunol 150:523-530, 2007
41. Berd D, Maguire HC Jr, Mastrangelo MJ: Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases äafter treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46:2572-2577, 1986
42. Berd D, Maguire HC Jr, McCue P, et al: Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients. J Clin Oncol 8:1858-1867, 1990
43. Berd D, Mastrangelo MJ: Effect of low dose cyclophosphamide on the immune system of cancer patients: Depletion of CD4+, 2H4+ suppressorinducer T cells. Cancer Res 48:1671-1675, 1988
44. Elias EG, Suter CM, Fabian DS: Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide. J Surg Oncol 64:17-22, 1997
45. MacLean GD, Miles DW, Rubens RD, et al: Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol 19:309-316, 1996
46. Hoon DS, Foshaq LJ, Nizze AS, et al: Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res 50:5358-5364, 1990
47. Mayordomo J, Tres A, Miles D, et al: Long-term follow-up of patients concomitantly treated with hormone therapy in a prospective controlled randomized multicenter clinical study comparing STn-KLH vaccine with KLH control in stage IV breast cancer following first-line chemotherapy. J Clin Oncol 22:188s, 2004 (abstr 2603)
48. Miles D, Papazisis K: Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer. Clin Breast Cancer 3:S134-S138, 2003